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Patients with the cerebrohepatorenal syndrome of Zellweger lack peroxisomes and 
certain peroxisomal enzymes such as dihydroxyacetone phosphate acyltransferase 
in their tissues. Deficiency of this enzyme, which is necessary for glycerol ether 
lipid synthesis, provides a biochemical method for recognizing patients with subtle 
manifestations of Zellweger syndrome and suggests the utility of exogenous ether 
lipid precursors as a therapeutic strategy for these children. We describe the 
results of glycerol ether lipid supplementation to two children, one with classic 
Zellweger syndrome and 9 % of control fibroblast dihydroxyacetone phosphate 
acyltransferase activity, and one with mild facial manifestations, wide sutures, 
hypotonia, developmental delay, hepatomegaly, peripheral retinal pigmentation, 
and 50 % of control fibroblast dihydroxyacetone phosphate acyltransferase activ- 
ity. An increase in erythrocyte plasmalogen levels following therapy was clearly 
demonstrated in the milder patient, and neither patient showed evidence of toxic- 
ity. Evaluation of therapy by comparison to the usual clinical course of Zellweger 
syndrome was not helpful because of the variability and incomplete documentation 
of 90 previously reported cases. The literature survey did provide criteria for 
classic Zellweger syndrome, which include hypotonia with or without deformation 
of limbs, large fontanels and split sutures, prominent forehead, flattened facial 
profile with hypoplastic supraorbital ridges, anteverted nares, highly arched pal- 
ate, cryptorchidism or labial hypoplasia, hepatomegaly or elevated liver enzymes, 
peripheral pigmentation of the retina, renal cortical cysts, and characteristic 
neuropathology involving decreased myelinization, abnormal neuronal migration, 
and sudanophilic macrophages. Less severe patients, as exemplified by our case 2 
and others from the literature, will not have all the classic features and can be 
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recognized only by a growing panel of biochemical indicators. Our patient studies 
illustrate the complexity of designing comprehensive therapy for Zellweger-like 
conditions, suggest other diseases that may involve peroxisomal alterations, and 
emphasize the need for multicenter, collaborative studies to evaluate biochemical 
heterogeneity and therapy of peroxisomal disorders. 
Key words: Zellweger syndrome, peroxisomes, glycerol ether lipids, plasmalogens, MCA/MR 
syndrome 
INTRODUCTION 
Zellweger syndrome (ZS) is a fatal autosomal recessive disorder; affected 
individuals have unusual physical features, severe neurologic dysfunction, hepato- 
renal disease, and diverse metabolic abnormalities [Bowen et al, 1964; Kelley, 19831. 
The important role of peroxisomes in lipid metabolism [Novikoff and Novikoff, 19821 
and their absence from ZS liver [Goldfischer et al, 19731 suggested that peroxisome 
deficiency may account for many alterations in ZS. Brown et a1 [1982] and Moser et 
a1 [1984] have demonstrated that very long chain fatty acids are increased in the 
plasma and fibroblasts of ZS patients, a finding that correlates with the selective 
oxidation of very long chain fatty acids by peroxisomes [Kawamura et al, 19811. The 
report by Heymans et a1 [ 19831 showing decreased plasmalogens in several ZS tissues 
supported the findings of Hajra [1968], Hajra et a1 [1979], and Hajra and Bishop 
[ 19821 , who demonstrated that certain enzymes necessary for plasmalogen biosyn- 
thesis are located in peroxisomes. This finding of plasmalogen deficiency led to 
studies by Schutgens et al [I9841 and Datta et al [I9841 demonstrating that the first 
enzyme in the pathway for plasmalogen synthesis (Fig. 1)-ie, dihydroxyacetone 
phosphate acyltransferase (DHAP-AT)-was deficient in the liver, leucocytes, and 
fibroblasts of ZS patients. 
Elevated very long chain fatty acid levels or deficiency of DHAP-AT thus 
provide prenatal [Solish et al, 1985; Hajra et al, 19851 or postnatal diagnostic assays 
for ZS, although normal levels in parents indicate that neither assay is a measure of 
the primary defect. In fact, since elevated long chain fatty acids [Moser et al, 19841 
and DHAP-AT deficiency [Hajra, personal communication] also occur in infantile 
adrenoleukodystrophy, these biochemical changes should be viewed as general char- 
acteristics of peroxisomal alteration, which must be associated with specific diagnostic 
categories by further morphologic and biochemical delineation. Nevertheless, since 
soluble peroxisomal enzymes and the distal enzymes of plasmalogen synthesis have 
significant activity in ZS fibroblasts [Datta et al, 1984; Wanders et al, 19841, dietary 
supplementation of plasmalogen precursors in order to bypass the DHAP-AT defi- 
ciency represents a possible strategy for treatment of this disorder. Incorporation of 
alkylglycerols into plasmalogens proceeds normally in ZS fibroblasts [Schrakamp et 
al, 19851. 
We report on a therapeutic trial of dietary ether lipid supplementation in a 
classic severe ZS patient and in one with milder symptoms that were diagnosed by 
documenting partial deficiency of DHAP-AT. Therapy appeared promising in the 
partially deficient patient, as judged by clinical improvement. Assessment of this 
treatment, particularly by comparison to historical controls, emphasizes the need for 
prospective evaluation of patients with ZS and related peroxisomal disorders. 
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Fig. I .  Pathways for acylglycerol and glycerol ether lipid synthesis. After synthesis from acyl coen- 
zyme A and DHAP (reaction I ) ,  acyl DHAP is a precursor for both acyl and alkyl glycerol lipids. 
Reduction of acyl DHAP to I-acyl glycerol-3-P (reaction 2) is one route for acylglycerolipid synthesis. 
Alternatively, acyl DHAP reacts with long chain alcohol to form I-0-alkyl DHAP (reaction 5) ,  the 
precursor for ether glycerolipid and plasmalogen synthesis. The enzymes catalyzing reactions 1 (DHAP- 
AT), 5 (alkyl DHAP synthase), and 2 or 6 (acyllalkyl DHAP:NADPH oxidoreductase) are localized 
mostly in peroxisomes and constitute the sole pathway for ether lipid synthesis, while G-3-P acyltrans- 
ferase (reaction 9) is located mostly in mitochondria and microsornes. Deficiency of DHAP acyltransfer- 
ase with residual activities of enzymes catalyzing reactions 2.5.6, and 9 in Z S  provides the rationale for 
correcting tissue plasmalogen deficiency by providing oral mixtures of chirnyl, batyl, and selachyl 
alcohols. 
CLINICAL REPORTS 
Patient 1 (Fig. 2A) 
This patient was described briefly in a prior report [Datta et al, 19841. She was 
the 4.05-kg (97th centile) product of a 43-week uncomplicated gestation to a G2 Po 
Abl 23-year-old mother and 30-year-old father. The family history was unremark- 
able. Her length was 51 cm (25th centile), occipitofrontal circumference (OFC) was 
35 cm (60th centile), the interpupillary distance was 4.5 cm (90th centile), and the 
intercanthal distance was 2.6 cm (> 97th centile). Facial anomalies included a high 
forehead, broad nasal root, highly arched palate, anteverted nares, micrognathia, and 
a flattened profile with hypoplastic supraorbital ridges. The anterior and posterior 
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Fig. 2. Patient I (A-age 6 weeks) and 2 (B-age 8 months) 
fontanels were enlarged and showed open metopic and sagittal sutures. There were 
epicanthal folds, upslanting palpebral fissures, Brushfield spots in the irides, cortical 
cataracts, and peripheral pigmentation of the retina. Other abnormalities included 
redundant nuchal skin, widely spaced nipples, hepatomegaly extending 4 cm below 
the right costal margin, bilateral simian creases, bilateral talipes equinovarus, hypo- 
plastic labia majora, and severe hypotonia. Neonatal intensive care for seizures and 
persistent fetal circulation included ventilator support, Priscoline@, and phenobarbital 
therapy. Computerized tomography (CT) scan and screen for congenital infection 
were normal, as were chromosomes. Serum iron was 112, total iron binding capacity 
was 370, serum glutamic oxaloacetic transaminase (SGOT) was 60 units per liter, 
and serum glutamic-pyruvic transaminase (SGPT) was 39 units per liter at age 1 
week. 
At age 5 weeks, a skeletal survey showed patellar enlargement with punctate 
calcification around the hips and retarded bone age; urine metabolic screen showed 
qualitatively elevated pipecolic acid, and renal ultrasound showed increased echogen- 
icity with no visible cysts. Deterioration began at age 12 weeks with increasing 
seizures and respiratory insufficiency. Trials of ether lipid supplementation are sum- 
marized in Figure 3. At age 8 %  months, the patient was stable at home but exhibited 
no developmental progress. The height was 70 cm (50th centile), weight was 8.71 kg 
(50th centile), OFC was 44.5 cm (50th centile), and the anterior fontanel was 
markedly enlarged (8 cm long by 6 cm wide). At age 10 months, she developed 
severe gastrointestinal bleeding and died from acute renal failure and respiratory 
insufficiency. A limited autopsy confirmed the cause of death and showed hepatome- 
galy and renal cortical cysts. 
Patient 2 (Fig. 28) 
This patient is a 20-month-old white male who was referred to evaluation of 
hypotonia, hepatomegaly, and failure to thrive. He was the 3.15-kg (25th centile), 54- 
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Fig. 3. The clinical course and timing of ether lipid supplcrncntation for patients I and 2. G . I . ,  
gastrointestinal; ERG, electroretinogram; BAER, brainstein auditory evoked response. Periods of ether 
lipid supplementation are indicated above thc time line by bars (H). 
cm (90th centile) product of a term uncomplicated gestation to a 23-year-old primi- 
gravida. The father was 27 years old and unrelated to the mother. Enlarged anterior 
and posterior fontanels with a widened sagittal suture were noted at birth; the OFC 
was 34.5 cm (60th centile). A cranial ultrasound study and skull films were normal. 
Admission at age 7 weeks demonstrated an open metopic suture, enlarged anterior (3 
x 3 cm) and posterior (1.5 X 1.5 cm) fontanels, a highly arched palate, poor head 
control, and slightly increased deep tendon reflexes. He had mild anemia (hemoglobin 
10.1 with normal red cell indices) with elevations of the following: serum bilirubin 
(1.2 mg per dl), alkaline phosphatase (495 units per liter), SGOT (912 units per liter), 
thyroid stimulating hormone (TSH) (21 IU per ml), and thyroid hormone (T4) (12.6 
pg per dl), iron saturation (51 %, compared to a normal of 20-25 %), and ferritin (814 
ng per ml). A urine amino acid screen, erythrocyte protoporphyrin, hemoglobin 
electrophoresis, TORCH screen, and serologic markers for HBV infection were 
normal. Percutaneous liver biopsy showed increased glycogen with fibrous septa and 
paucity of intrahepatic biliary ducts. At age 9 months, ophthalmologic evaluation 
showed inconsistent fixation and following of light, vertical nystagmus, right esotro- 
pia, punctate cortical and nuclear sclerosis lens changes bilaterally with no cataracts, 
marked peripheral retinal pigmentary changes, and gray optic discs of normal size. 
Visual evoked response and electroretinogram performed under general anesthesia 
showed no photopic or scotopic responses, suggesting a poor outlook for vision. At 
age 14 months, the patient's height was 78 cm (50th centile), weight was 8.8 kg (5th 
centile), OFC was 47 cm (25th centile), and the anterior fontanel continued to be 
enlarged (8 x 6 cm) with an open metopic suture. The posterior fontanel was closed. 
He had long eyelashes, a broad nasal root (intercanthal distance 2.4 cm-50th centile; 
interpupillary distance 4.5 cm-50th centile), a shallow nasal bridge, a highly arched 
palate, an enlarged liver that was palpable 5 cm below the right costal margin, 
increased joint laxity with hypotonia, and increased deep tendon reflexes. An initial 
lipoprotein electrophoresis showed a low or absent pre-beta band that suggested 
abetalipoproteinemia, but two subsequent analyses were normal. Chromosomes and 
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leucocyte lysosomal enzyme panel were normal. Muscle biopsy of the rectus abdom- 
inus showed normal muscle with predominance of type I fibers. Continued slow 
growth, poor vision, hypotonia, and developmental delay prompted a trial of oral 
ether lipid supplementation at age 14% months (Fig. 3). At age 20 months, increased 
very long chain fatty acids (C26 of 1.49 pg/ml vs 0.33 pg/ml for control; C26/C22 
0.225 vs 0.04 for control) were detected in the serum [Moser, personal 
communication]. 
METHODS 
Assays for DHAP-AT, acyl/alkyl DHAP reductase, alkyl DHAP synthase, and 
glycerol-3-phosphate acyl transferase were performed as described previously [Datta 
et al, 19841. Fibroblasts were trypsinized, washed with 25 mM Tris-HC1, 5 mM KC1, 
140 mM NaCl, 0.5 mM EDTA at pH 7.4 and stored frozen before assay. Frozen liver 
or fibroblasts were homogenized in 10 volumes of 0.25 M sucrose containing Tris- 
HCI(l0 mM, pH 7.4) and EDTA ( I  mM) prior to assay. 
Plasmalogens were measured on packed red cells that had been washed as 
described for fibroblasts. Lipids were extracted with chloroform-methanol and washed 
as described by Folch et a1 119571, and plasmalogens were assayed from 0.5 ml of 
packed red cells using the methods of Horrock [ 19681. Quantitative measurements of 
alkylglycerol ethers and plasmalogens were performed by treating the lipid extract 
with Red-A1 followed by thin-layer chromatography [Wood and Synder, 19681. 
The ether lipid mixture for patient 1 contained 400 mg of chimyl alcohol (see 
Fig. l ) ,  400 mg of batyl alcohol, 200 mg of selachyl alcohol, 150 mg of egg lecithin, 
and 200 mg of sodium deoxycholate (all from Sigma Chemical Co., St. Louis, MO) 
in 100 ml of water emulsified by sonication in a Branson sonifier for 15 minutes at 
70% power with the large probe. For patient 2, the selachyl alcohol and egg lecithin 
were omitted. Each patient received 1 ml of ether lipid suspension five times daily 
with feedings, representing 50 mg ether lipid per 5-8 kg daily for patient 1 (6-10 mg/ 
kg) and 40 mg ether lipid per 7-10 kg daily for patient 2 (4-6 mg/kg). These dosages 
are well below those amounts of alkylglycerols that have been administered to adults 
without complication [Mangold, 19731. 
RESULTS 
Table I summarizes the activities of DHAP-AT and other enzymes in the 
fibroblasts and liver from patients 1 and 2. Whereas classic ZS patients such as patient 
1 have negligible fibroblast DHAP-AT activity [Datta et al, 19843, patient 2 has 50% 
of control activity, which correlates with his milder phenotype. Liver DHAP-AT 
activities are negligible in both cases, whereas other lipid-synthesizing enzymes have 
intermediate activity. This may reflect their dependence upon peroxisome structure 
or, in the case of glycerol-3-phosphate acyltransferase, concurrent alterations of 
mitochondria and the endoplasmic reticulum which have been reported in ZS [Gold- 
fischer, 19731. 
Figure 3 illustrates the course of ether lipid therapy in both cases. Patient 1 
received therapy for about 5 months during the indicated periods with interruptions 
owing to suspected infection or gastric distension. Patient 2 has received therapy for 
5 Yz months continuously without obvious complications such as elevated liver en- 
zymes or gastrointestinal problems. No subjective or objective benefits of therapy 
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TABLE I. Activities of Lipid-Synthesizing Enzymes in Patients 1 and 2 
nrnol/niin/rng protein 
PH Patient 1 Patient 2 Control 
DHAP Acyltransferase 
Fibroblast 1 .4  0.01" 0.14 0.28 f 0.05" 
5.5 0.02" 0.13 0.21 0.03" 
Leucocyte I .4 0.01 0.06 0.16 
5.5 0.02 0.06 0.26 
Liver 7.4 N D ~  0.05 0.46 
5.5 0.08 0.36 
Glycerol-3-phosphate acyltransferase 
Fibroblast 0.65" 1.15 1.28 f O.2Ot 
Leucocy te 0.10 0.11 0.31 
Liver ND 0.46 0.55 
Fibroblast 0.02" 0.08 0.14 f 0.02" 
Liver ND 0.14 0.35 
Fibroblast 1.36" 1.42 1.48 f 0.18" 
Liver ND 0.91 I .09 
Alkyl DHAP synthase 
Alkyl/acyl DHAP: NADP reductase 
aFrom Datta et a1 [ 19841. 
%D = not done. 
could be discerned for patient 1, and the occasional increases in hepatic enzyme levels 
were thought to be due to other causes as they did not always correlate with the 
initiation or cessation of ether lipid supplementation. 
After three months of therapy, the parents and physicians involved with patient 
2 noted improvement of growth (increasing from the 5th to 25th centile) and muscle 
tone (acquisition of sitting-up and cruising skills). He had decreased nystagmus with 
improved ability to fixate and to follow light. A fundoscopic examination showed 
gray optic discs with virtual disappearance of the prominent retinal pigmentation 
observed at age 9 months. However, an electroretinogram repeated at age 20 months 
again showed an extinguished response that was essentially unchanged from the 
previous study. 
An increase in erythrocyte phosphoethanolamine plasmalogen levels in patient 
2 at both 5% and 7% months after ether lipid supplementation is shown in Table 11. 
Little change was observed in other lipid classes. Quantitative plasmalogen determi- 
nations were not performed on patient 1. Baseline erythrocyte plasmalogen levels in 
patient 2 were higher than those for patients with classic ZS [Heymans et al, 19831, a 
feature consistent with his milder phenotype. 
DISCUSSION 
Complementary advances in the understanding of peroxisome function and the 
consequences of peroxisome deficiency in ZS have provided diagnostic assays and 
therapeutic strategies for this severe malformation syndrome. The need to evaluate 
biochemical heterogeneity and potential therapy in ZS prompted a review of those ZS 
patients reported in the literature or seen at our institution. Clinical and pathologic 
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TABLE 11. Phospholipid Composition of Erythrocytes (Patient 2) Before and After Ether Lipid 
Therapy* 
Age (months) 
Lipid class 14 20 22 Control 
Polar lipids 7.8 8.1 4.5 5.1 
PS + PI 12.6 12.2 9.8 11.0 
Sphingomyelin 29.4 26.1 23.8 30.5 
PC 34.5 32.9 34.9 31.5 
PE 9.4 12.4 15.1 10.2 
*Values represent percent of total phospholipids as PS, phosphatidyl serine; PI, phosphatidyl inositol; 
PC, phosphatidyl choline; PE, phosphatidyl ethanolamine. Erythrocyte samples were obtained at age 14 
months (before treatment), 20 months (after 5% months of treatment), and 22 months (after 7% months 
of treatment). 
PC plasmalogen 2.7 2.3 2.0 2 .  I 
PE plasmalogen 4.0 7.9 9.8 9.5 
features of 83 literature cases and 7 cases of our own (not including patients 1 and 2) 
who were judged to have classic ZS are summarized in Table 111. Excluded from the 
survey were cases that were minimally described or atypical, eg, those of Gatfield et 
a1 [1968] or Thomas et a1 [1975] in which high serum pipecolic acid levels were 
present but the typical clinical features were absent. 
Common manifestations such as hypotonia with or without accompanying de- 
formations, large fontanels and split sutures, hepatomegaly or elevated liver enzymes, 
peripheral pigmentation of the retina, and the typical malformations (high forehead, 
flattened facial profile, simian creases, malformed ears, high palate, shallow/broad 
nasal bridge with anteverted nares, cryptorchidism, or labial hypoplasia) should 
prompt consideration of a Zellweger-like condition. Patient I ,  for example, had 28 of 
32 features for which she was evaluated in Table I11 (44 features total) and would 
represent a classic ZS patient. Patient 2 had only 15 of 32 features in Table I11 and 
represents a new disease category with partial manifestations of ZS which can be 
recognized by clinical and biochemical criteria. Other patients who might be included 
in this category are those with pipecolic aciduria [Thomas et al, 1975; Gatfield, 19681, 
those with infantile adrenoleukodystrophy [Brown et al, 19821, those with infantile 
Refsum’s disease [Poulos et al, 19841, and the atypical case of Versmold et a1 [ 19771. 
Previous results from our laboratories [Datta et al, 19841, as summarized in 
Table I, suggest that the enzyme DHAP-AT has an obligate relationship to peroxisome 
biogenesis and is almost completely deficient in tissues of patients with classic ZS. 
Enzymes such as catalase, which in many normal tissues are located in peroxisomes, 
can assume a cytoplasmic location in ZS and have normal activity. Enzymes such as 
alkyl DHAP synthase and acyl/alkyl DHAP reductase (reactions 5 and 2 or 6 in Fig. 
1) have either an intermediate dependence on peroxisome biosynthesis or are partially 
distributed in peroxisomal and microsomal compartments in normal cells; such en- 
zymes have intermediate activities in ZS tissues. Glycerol-3-phosphate acyltransferase 
is not primarily located in peroxisomes and is used as a reference activity in our 
clinical assays. Partial reduction of this activity in certain ZS tissues may reflect 
concomitant alteration of mitochondria and endoplasmic reticulum as suggested by 
Goldfischer et a1 [ 19731. 
Peroxisome-dependent enzymes such as DHAP-AT, while not useful as a mea- 
sure of the primary defect [Datta et al, 19841, provide a good criterion for peroxisomal 
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TABLE 111. Clinical Manifestations of Classic Zellweger Syndrome” 
Female Male 
Cases 47 43 
Mean birth weight 2,740 2,730 
Prenatal growth failure 6/47 (13 %) 11143 (25%) 
Postnatal growth failure 25127 (92%) 19/20 (95%) 
Mean age at death 38- 12.2 41-12.9 
(No. patients-wk) 
(No. patients-wk) 






Flat supraorbital ridges 
Epicanthal folds 
“Hypertelorism,” broad nasal 
root 
Anteverted nares 




Pallidlhypoplastic optic disc 
Retinal pigmentary changes 
Hepatomegaly 
Elevated liver enzymes 
Gastrointestinal bleeding 
Cirrhosis 
Hepatic iron storage 
































Talipes cquinovarus 33/59 56 
Ulnar deviation 9/59 15 
Camptodactyly 6159 10 
Simian creases 26133 79 
Radiographic stippling 4 1/59 69 
Cryptorchidism 27136 75 
Clitoral hypertrophy/ 
hypoplastic labia 519 56 
Hypotonia 83184 99 
Seizures 35/44 80 
Pachymicrogyria 31146 61 
Heterotopiaslabnormai migration 22/46 48 
Subependymal cysts 17146 37 
Astrocytosis, gliosis 16/46 35 
Sudanophilic macrophages 12146 26 
Abnormal myelinization 10146 22 
Hypoplastic corpus callosum 9146 20 
Hypoplastic olfactory lobes 3146 7 




Elevated urine pipecolate 20126 77 
*Patients are summarized from the reports of Agamonolis et al [1976], Arneson et a1 [1982], Bartoletti 
et a1 [1978], Bowen et al (19641, Brun et al [1978], Danks et al [1975], Deleon et al [1977), Evrard et 
al 119781, Garzuly et al [1974], Gilchrist et al [1976], Govaerts et al [1983], Gustafsson et al [1983], 
Hittner et al 119811, Jan et al [1970], Liu et al [1976], Opitz et al 119691, Passarge and McAdams 
119671, Patton et al (19721, Poznanski et al [1970], Punnett and Kirkpatrick [1968], Sommer et al 
(19741, Smith et al (1965, Vincens et al [1973], Volpe and Adams [1972], and Williams et a1 [19721. 
The patients of Vitale et al ( 19691 appear to be included in the report of Opitz et al [1969]. 
alteration, as demonstrated by the partial deficiency in patient 2. One can speculate 
that one or more proteins responsible for peroxisome biogenesis will represent the 
gene product(s) altered in Zellweger-like conditions and that DHAP-AT activity is in 
some way dependent upon normal peroxisome structure. Since DHAP-AT is unstable, 
it is extremely important to include control tissues stored under equivalent conditions 
and to assay related enzymes as an indicator of tissue preservation before concluding 
that there is a partial deficiency. 
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Because deficiency of DHAP-AT would predict deficient synthesis of glycerol 
ether lipids and plasmalogens, as has in fact been documented in ZS [Heymans et al, 
19831, a trial of oral glycerol ether lipid therapy was tried in both patients. Oral 
supplementation definitely increased erythrocyte plasmalogens in patient 2 (Table II), 
as measured by quantitative thin-layer chromatography. Such increases must reflect 
incorporation of alkylglycerols into membrane lipids during erythropoiesis, as the 
distal enzymes for plasmalogen synthesis (Fig. 1) are not present in circulating 
erythrocytes. The lack of consistent side effects in either patient (Fig. 3) supports the 
low risk status of glycerol ether lipids previously deduced by oral administration to 
adults [Mangold, 19731. While striking, the apparent clinical improvement in patient 
2 must be viewed with skepticism until better delineation of peroxisomal disorders 
and their natural history is achieved. Also, conclusions about neurologic improvement 
should await definitive proof of the ability (not unlikely for lipid-soluble molecules) 
that alkylglycerols cross the blood-brain barrier. An attempt to compare the influence 
of therapy in patient I to the usual natural history of ZS was frustrated by the variable 
severity and incomplete documentation of ZS patients illustrated by the data in Table 
111. Improvement in growth and overall nutrition was noted in patient 1 after therapy, 
but the incidence of complications seemed similar to those of previously reported 
patients. No developmental progress was noted. 
Obviously, oral ether lipid therapy and the rather arbitrary mixture of alkyl 
glycerols employed here represents only a beginning in the treatment of the multiple 
consequences imposed by peroxisome deficiency. Comprehensive therapy for peroxi- 
some deficiencies might involve dietary restriction of long chain fatty acids, since 
these have been shown to be exogenously provided [Kishimoto et al, 19801, and 
provision of bile salts [Hanson et al, 19791 in addition to ether lipid supplementation. 
Replacement of adrenal steroids should also be considered, particularly during stress 
[Govaerts et al, 19841. Even with these efforts, coexisting alterations of mitochondria1 
and microsomes [Goldfischer, 19731 might not be amenable to treatment in severely 
affected patients. 
One may ask whether patient 2 has a mild form of ZS or another disease such 
as infantile adrenoleukodystrophy. While patients with infantile adrenoleukodystro- 
phy lack the pronounced facial changes, renal cortical cysts, and skeletal anomalies 
associated with ZS, they do have peroxisome deficiency, elevated very long chain 
fatty acids, pipecolic acidemia, altered bile metabolism, hypotonia, and demyeliniza- 
tion in common with ZS [Goldfischer et al, 19851. In addition, six previously reported 
cases of neonatal adrenoleukodystrophy [Ulrich et al, 1978; Benke et al, 1981; Jaffe 
et al, 1982; Haas et al, 19821 have exhibited a severe degenerative course, although 
one patient’s development peaked as late as age 2 years [Haas et al, 19821. The wide 
fontanels and split sutures of patient 2, along with the subtle facial anomalies and 
improving clinical course lead us to classify him as a mild form of ZS. Patient 2 
illustrates the need for a multicenter prospective registry to aid in the differential 
diagnosis, biochemical delineation, and assessment of treatment for patients with 
peroxisomal disorders. 
Once systematic investigation is initiated, there is likely to be a large list of 
disorders that involve alteration of peroxisome function. Both Refsum’s disease and 
cerebrotendinous xanthomatosis may belong to a peroxisomal disease category [Gold- 
fischer, 19821 and have responded to therapy based on dietary avoidance of phytanic 
acid or supplementation of a deficient metabolite (bile salts). Abetalipoproteinemia is 
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another disorder worth evaluating for peroxisomal alterations, because ( I )  certain 
infants with that disorder have had severe hypotonia and retinitis pigmentosa, (2) 
certain ZS patients including patient 2 have had transient reports of low betalipopro- 
tein, and (3) there is a clear relationship between peroxisome density and lipoprotein 
metabolism as indicated by the effects of clofibrate [Reddy et al, 19821. The increased 
hepatic glycogen in classic or mild ZS, particularly in our patient 2, also suggests a 
link between peroxisome or endoplasmic reticulum alterations and glycogen 
metabolism. 
The implications of peroxisome deficiency and altered lipid metabolism as a 
central cause for the altered morphogenesis in ZS are many. A clear relationship 
among peroxisome function, lipid metabolism, and neurogenesis now exists and can 
be defined in animal models. Certain of the many neurologic mutants of the mouse 
are well worth screening for peroxisomal alterations. The cause of disorders involving 
cerebral dysgenesis, such as the various conditions involving lissencephaly [Dobyns 
et al, 19841, should be approached with the many roles of peroxisomes in mind. The 
importance of lipid metabolism in embryogenesis should be given increased emphasis, 
particularIy since certain cellular growth factors contain glycerolipid cofactors [Cooper 
et al, 19841. 
It is worth emphasizing the role of clinical genetics in defining ZS as an entity 
and in providing a useful mutant that will not contribute much to the understanding 
of peroxisome function. Careful morphometric evaluation and clinical follow-up 
should be components in the registry of patients with peroxisomal disorders. It is 
unfortunate that an established syndrome like ZS has the rather fragmentary record 
of clinical and biochemical findings (Table HI) which limit our attempts to judge 
therapy. Without increased emphasis, the “experiments of nature” that human mal- 
formation syndromes represent will either be unobserved or their results inadequately 
recorded. 
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